| Deep learning in cancer diagnosis, prognosis and treatment selection KA Tran, O Kondrashova, A Bradley, ED Williams, JV Pearson, N Waddell Genome medicine 13, 1-17, 2021 | 621 | 2021 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 406 | 2017 |
| Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, ... Nature communications 9 (1), 3970, 2018 | 265 | 2018 |
| CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer E Sanij, KM Hannan, J Xuan, S Yan, JE Ahern, AS Trigos, N Brajanovski, ... Nature communications 11 (1), 2641, 2020 | 131 | 2020 |
| Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma K Nesic, O Kondrashova, RM Hurley, CD McGehee, CJ Vandenberg, ... Cancer Research 81 (18), 4709-4722, 2021 | 70 | 2021 |
| Verifying explainability of a deep learning tissue classifier trained on RNA-seq data M Yap, RL Johnston, H Foley, S MacDonald, O Kondrashova, KA Tran, ... Scientific reports 11 (1), 2641, 2021 | 64 | 2021 |
| Targeting DNA repair: the genome as a potential biomarker K Nesic, M Wakefield, O Kondrashova, CL Scott, IA McNeish The Journal of pathology 244 (5), 586-597, 2018 | 54 | 2018 |
| Next batter up! Targeting cancers with KRAS-G12D mutations MN Zeissig, LM Ashwood, O Kondrashova, KD Sutherland Trends in cancer 9 (11), 955-967, 2023 | 45 | 2023 |
| Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma J Creaney, AM Patch, V Addala, SA Sneddon, K Nones, IM Dick, YCG Lee, ... Genome medicine 14 (1), 58, 2022 | 41 | 2022 |
| Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance RM Hurley, CD McGehee, K Nesic, C Correia, TM Weiskittel, RL Kelly, ... Nar Cancer 3 (3), zcab028, 2021 | 34 | 2021 |
| An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice G Ellison, M Ahdesmäki, S Luke, PM Waring, A Wallace, R Wright, ... Human mutation 39 (3), 394-405, 2018 | 34 | 2018 |
| Heritable defects in telomere and mitotic function selectively predispose to sarcomas ML Ballinger, S Pattnaik, PA Mundra, M Zaheed, E Rath, P Priestley, ... Science 379 (6629), 253-260, 2023 | 33 | 2023 |
| Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer VF Bonazzi, O Kondrashova, D Smith, K Nones, AT Sengal, R Ju, ... Genome Medicine 14, 1-19, 2022 | 32 | 2022 |
| CRISPR/Cas9‐mediated genome editing of Schistosoma mansoni acetylcholinesterase H You, JU Mayer, RL Johnston, H Sivakumaran, S Ranasinghe, V Rivera, ... The FASEB Journal 35 (1), e21205, 2021 | 31 | 2021 |
| Performance of tumour microenvironment deconvolution methods in breast cancer using single-cell simulated bulk mixtures KA Tran, V Addala, RL Johnston, D Lovell, A Bradley, LT Koufariotis, ... Nature Communications 14 (1), 5758, 2023 | 26 | 2023 |
| Diverse mechanisms of PARP inhibitor resistance in ovarian cancer MJ Wakefield, K Nesic, O Kondrashova, CL Scott Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1872 (2), 188307, 2019 | 26 | 2019 |
| BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus–associated T/NK-cell lymphoma N Sejic, LC George, RJ Tierney, C Chang, O Kondrashova, ... Blood Advances 4 (19), 4775-4787, 2020 | 20 | 2020 |
| The role of aberrant DNA methylation in cancer initiation and clinical impacts F Geissler, K Nesic, O Kondrashova, A Dobrovic, EM Swisher, CL Scott, ... Therapeutic Advances in Medical Oncology 16, 17588359231220511, 2024 | 19 | 2024 |
| Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels P Ramarao-Milne, O Kondrashova, AM Patch, K Nones, LT Koufariotis, ... ESMO open 7 (4), 100540, 2022 | 18 | 2022 |
| Epithelial-to-Mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule targeting with eribulin GY Ho, EL Kyran, J Bedo, MJ Wakefield, DP Ennis, HB Mirza, ... Cancer Research 82 (23), 4457-4473, 2022 | 14 | 2022 |